Natural History and Risk Stratification of Biochemically Recurrent Prostate Cancer Following Definitive Radiation Therapy
A simple, 2-element risk stratification tool using existing clinical data is the first validated tool for identifying patients at risk of metastases or prostate cancer-specific mortality following postradiation BCR. Most patients experiencing BCR in this context do not develop metastases or lethal prostate cancer, making such stratification essential for treatment decision-making and refinement of patient populations for clinical trials.
Authors
- J. Kellogg Parsons
- Leah Deshler
- Tyler F. Stewart (ORCID: https://orcid.org/0000-0002-8170-264X)
- Brent Shane Rose (ORCID: https://orcid.org/0000-0002-3197-9552)
- Paul Riviere (ORCID: https://orcid.org/0000-0001-7966-3090)
- Daniel Sabater Minarim
- Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
- Juan Javier‐Desloges (ORCID: https://orcid.org/0000-0003-1120-9144)
- Tyler J. Nelson (ORCID: https://orcid.org/0000-0001-5216-7337)
- Kylie Morgan (ORCID: https://orcid.org/0000-0002-2776-2721)
- Matthew P. Banegas (ORCID: https://orcid.org/0000-0002-6158-7162)
Institutions
- University of Michigan (US)
- UC San Diego Health System (US)
- University of California San Diego (US)
- Fred Hutch Cancer Center (US)
- Therapeutics Clinical Research (US)
Publication Details
- Journal
- Advances in Radiation Oncology
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1016/j.adro.2025.101936
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense